Methocarbamol and Inbrija drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Methocarbamol (methocarbamol) and Inbrija (levodopa). Common drug interactions include tremor among females and parkinson's disease among males.
The phase IV clinical study analyzes what interactions people have when they take Methocarbamol and Inbrija. It is created by eHealthMe based on reports of 25 people who take the same drugs from the FDA, and is updated regularly.
What is Methocarbamol?
Methocarbamol has active ingredients of methocarbamol. It is often used in muscle spasms. eHealthMe is studying from 17,766 Methocarbamol users. Check the latest studies of Methocarbamol.
What is Inbrija?
Inbrija has active ingredients of levodopa. eHealthMe is studying from 7,848 Inbrija users. Check the latest studies of Inbrija.
25 people who take Methocarbamol and Inbrija together, and have interactions are studied.
What are the common drug interactions of Methocarbamol and Inbrija, by gender? *:
female:
- Tremor (trembling or shaking movements in one or more parts of your body)
- Parkinson's disease
- Drug ineffective
- Adverse drug reaction
- Mucosal discolouration (change in colour of mucosal membrane)
- Therapeutic response unexpected
- Tooth discolouration (a change in colour of teeth)
- Tooth fracture
- Constipation
- Disturbance in attention
male:
- Parkinson's disease
- Cough
- Drug ineffective
- Fall
- Dyskinesia (abnormality or impairment of voluntary movement)
- Eosinophil count increased
- Joint injury
- Sleep disorder
What are the common drug interactions of Methocarbamol and Inbrija, by age (0-1 to 60+)? *:
0-1:
n/a
2-9:
n/a
10-19:
n/a
20-29:
n/a
30-39:
n/a
40-49:
n/a
50-59:
- Fall
- Eosinophil count increased
- Joint injury
60+:
- Cough
- Tremor (trembling or shaking movements in one or more parts of your body)
- Feeling jittery
- Gait disturbance
- Mucosal discolouration (change in colour of mucosal membrane)
- Parkinson's disease
- Drug ineffective
- Dyskinesia (abnormality or impairment of voluntary movement)
- Tooth discolouration (a change in colour of teeth)
- Tooth fracture
What are the existing conditions these people have? *
- Parkinson's Disease: 25 people, 100.00%
- On And Off Phenomenon: 16 people, 64.00%
* Approximation only. Some reports may have incomplete information.
Do you take Methocarbamol and Inbrija?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
- Methocarbamol (17,766 reports)
- Inbrija (7,848 reports)
Browse all drug interactions of Methocarbamol and Inbrija:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Methocarbamol:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Inbrija:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Methocarbamol and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Inbrija and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zHow the study uses the data?
The study uses data from the FDA. It is based on methocarbamol and levodopa (the active ingredients of Methocarbamol and Inbrija, respectively), and Methocarbamol and Inbrija (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Hallucinations and drugs of ingredients of cephalexin - a second ago
- Could Lyrica cause Obstruction? - a second ago
- Drug interactions of Mycelex and Tacrolimus - a second ago
- Could Prilosec cause Allergic Rhinitis? - 3 seconds ago
- Etodolac and Plantar Fasciitis for Women aged 50-59 - 8 seconds ago
- Gastroesophageal Reflux Disease in Betapace, how severe and when it was recovered? - 8 seconds ago
- Eye Infection and drugs of ingredients of pitavastatin calcium - 10 seconds ago
- Cytarabine and Agranulocytosis for Men aged 40-49 - 17 seconds ago
- Cytarabine and Neutropenia for Men aged 40-49 - 18 seconds ago
- Cytarabine and Granulocytopenia for Men aged 40-49 - 18 seconds ago